FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

U.S. and EU regulatory approvals expand Opdivo's label to include Hodgkin lymphoma, broadening Bristol Myers' immunotherapy franchise and supporting its growth outlook. The approvals strengthen BMY's competitive position in oncology and are likely to drive incremental sales and market share in hematologic oncology.

Analysis

U.S. and EU regulatory approvals expand Opdivo's label to include Hodgkin lymphoma, broadening Bristol Myers' immunotherapy franchise and supporting its growth outlook. The approvals strengthen BMY's competitive position in oncology and are likely to drive incremental sales and market share in hematologic oncology.